Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Clinical trial NCT00093080 · COMPLETED

Trial details

NCT number: NCT00093080
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Leiomyosarcoma Liposarcoma Osteosarcoma Sarcoma, Soft Tissue Metastases

Start date: 2004-10-01
Primary completion: 2008-11-01
Enrollment: 216

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.